Format

Send to

Choose Destination
Acta Paediatr. 2005 Jun;94(6):779-84.

A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome.

Author information

1
Division of Neonatology, Department of Pediatrics, Ronald McDonald Children's Hospital at Loyola University Medical Center, Maywood, IL 60153, USA. c-malloy@northwestern.edu

Abstract

AIM:

To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS).

METHODS:

Infants with RDS were randomized to receive beractant or poractant. The primary outcome measure was fraction of inspired oxygen (FiO2) requirement in the first 48 h after surfactant therapy.

RESULTS:

58 infants completed the study. The mean gestational ages for the poractant and beractant groups were 29.6+/-3.6 and 29.3+/-2.9 wk, with average birthweights of 1394+/-699 and 1408+/-534 g, respectively. In the first 48 h, infants who received poractant had a lower FiO2 requirement compared to those who received beractant (p=0.018). The prevalence of patent ductus arteriosus (PDA) was lower in the group of infants that received poractant (17%) compared to the group that received beractant (45%) (p=0.02).

CONCLUSIONS:

Infants with RDS treated with poractant had a lower FiO2 requirement during the first 48 h compared to infants who received beractant. Infants who received poractant also had fewer PDAs than infants who received beractant. The difference in FiO2 was not associated with a difference in age of first extubation, total intubation time, or incidence of bronchopulmonary dysplasia between groups.

PMID:
16188788
DOI:
10.1080/08035250510028740
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center